Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PDS Biotechnology ( (PDSB) ) has issued an announcement.
On July 10, 2025, PDS Biotechnology announced the completion of patient recruitment for Stage 1 of a clinical trial involving its PDS01ADC therapeutic for metastatic colorectal cancer. The trial, led by the National Cancer Institute, met criteria for expansion into Stage 2, indicating promising results and potential advancements in cancer treatment.
The most recent analyst rating on (PDSB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.
Spark’s Take on PDSB Stock
According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.
PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.
To see Spark’s full report on PDSB stock, click here.
More about PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers and is involved in multiple phase 2 trials for various cancer indications.
Average Trading Volume: 520,552
Technical Sentiment Signal: Sell
Current Market Cap: $58.05M
Find detailed analytics on PDSB stock on TipRanks’ Stock Analysis page.